Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

P53 FUSION PROTEIN AS AN ONCOLOGY THERAPEUTIC

Award Number: R43CA124001
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/18/2007
PERIOD OF PERFORMANCE END DATE: 02/28/2009

Group Awards By:

View Award Description

P53 FUSION PROTEIN AS AN ONCOLOGY THERAPEUTIC - DESCRIPTION (provided by applicant): The aim of this proposal is to test the feasibility of the use of a p53 fusion protein as a cancer therapeutic. World wide 10 million people are diagnosed every year with cancer. 50% of human cancers involve a mutation in the p53 gene. In addition, these mutations are frequently found in solid tumors that are resistant to conventional therapies. These facts clearly demonstrate that p53 is an important target for anti-neoplastic therapies. Development of a novel p53- targeted anti-neoplastic therapeutic has the potential to save millions of lives worldwide each year, yet there are currently no FDA approved cancer therapies targeting this gene product. Using a patented refolding technology developed at ProteomTech, Inc., Pt-Fold, we have identified conditions that allow us to produce large amounts of stable tetrameric recombinant human p53 protein. To our knowledge, we are the only group that has been successful in accomplishing this. However, an efficient means of delivering this protein into cells is required for a successful protein therapeutic. We propose to achieve intracellular delivery by producing a form of p53 that is fused to a peptide that will mediate cell entry. Feasibility issues that will be addressed in phase 1 of this application include expression, refolding, purification and functional testing of the fusion proteins in p53-deficient cancer cell lines. Our goal of phase I of the proposal is to identify the best fusion protein for pre-clinical studies for a Phase II application. Development of a novel anti-neoplastic therapeutic for cancers that are characterized by a mutation if p53 and refractory to current therapies would represent a significant contribution to the oncology field and has the potential to benefit millions of people each year. According to the International Agency for Research on Cancer (IARC), world wide 10 million people will be diagnosed every year with cancer. Furthermore, the IARC estimated that up to half of all human cancers carry an inactivating mutation in the p53 gene. P53 mutations are frequently found in solid tumors that are resistant to conventional therapies. Despite the importance of this target, there are currently no FDA approved cancer therapies targeting p53. The aim of this proposal is to test the feasibility of the use of a p53 fusion protein as a novel cancer therapeutic.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2009 ( Subtotal = $0 )
2009	2007	PROTEOM TECH INC	3505 CADILLAC AVE #F7	COSTA MESA	CA	92626	ORANGE	USA	Cancer Treatment Research	000	1	12/31/2008	NEW	$0
2009	2007	GENECOPOEIA INC	19520 AMARANTH DRIVE	GERMANTOWN	MD	20874	MONTGOMERY	USA	Cancer Treatment Research	001	2	12/3/2008	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2007 ( Subtotal = $100,000 )
2007	2007	PROTEOM TECH INC	3505 CADILLAC AVE #F7	COSTA MESA	CA	92626	ORANGE	USA	Cancer Treatment Research	000	1	9/18/2007	NEW	$100,000
														Subtotal = $100,000

Grand Total All Awards = $100,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

P53 FUSION PROTEIN AS AN ONCOLOGY THERAPEUTIC

Award Number: R43CA124001

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/18/2007

PERIOD OF PERFORMANCE END DATE: 02/28/2009

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer